SRH Commodities: Data Collection Report – Kenya 2017

Statement on European Commission Proposal on Health Technology Assessments

Statement to WHO Executive Board 142: Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property

Statement to WHO Executive Board 142: Addressing the Global Shortage of, and Access to, Medicines and Vaccines

Statement to WHO Executive Board 142: Addressing the Burden of Snakebite Envenoming


Pharmaceutical Marketing: Report on Education on Pharmaceutical Promotion in Medical Training

Health Action International and European Public Health Alliance Reaction to Leaked Documents from EU-Mercosur Trade Talks

Joint Letter in Reaction to Council Conclusions on FP9

Joint Letter on the Final Phases of EU-Mercosur Trade Talks

Health Action International Launches Programme to Improve Snakebite Situation in Kenya

HAI Snakebite Programme – Kenya

Health Action International Statement on World Health Organization’s General Programme of Work

Recommendations on a New Model for the Provision of Scientific Advice

HAI Consultation Response on World Health Organization’s 13th General Programme of Work (GPW13)

Joint Letter to Jeremy Hunt – Environmental Pollution at Pharma Factories

SRH Commodities: Measuring Prices, Availability & Affordability (Methodology & Data Entry Manual)

Recommendations to Strengthen WHO EURO Member State Collaboration on Improving Access to Medicines

Joint Letter to OECD on Sustainable Access to Innovative Therapies

Pharmaceutical Promotion in Medical and Pharmacy Education in The Netherlands: Readiness for Curriculum Change

Scenario 6: Sustainable Europe for Its Citizens

HAI & Global Snakebite Initiative Applaud WHO’s Adoption of Snakebite Envenoming as Top-level Neglected Tropical Disease

Media Release: Health Action International Commend Decision By World Health Organization Not To Include Long-Acting Analogue Insulins On The Essential Medicines List

Joint Letter to Jean-Claude Juncker: EU Health Collaboration is Crucial for Europe’s Future

European Union Leadership Critical for Affordable & Responsible Antibiotic R&D

Response to Health Canada on Release of Clinical Data

Proposed Changes to EMA’s Access to Documents Policy Fall Short on Proactive Disclosure

Joint Response to EMA Consultation on Its Access to Documents Policy

Joint Letter to World Health Assembly Delegates | We must delink research and development costs from cancer medicine prices

Response to OECD Online Consultation ‘Sustainable access to innovative therapies’

Statement to the WHO Expert Committee on Selection and Use of Essential Medicines